Explore Products
Primary Cells

Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Relapsed/Refractory)

  • BSL

    1

  • 209
Multiple Myeloma Peripheral Blood Mononuclear Cells are isolated from Multiple Myeloma-peripheral blood by diluting the blood with phosphate-buffered salineand using gradient separation techniques. After centrifugation, the Mononuclear Cells layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Multiple Myeloma PBMCs products are available in both the newly diagnosed and the relapsed/refractory stages.
Request Your Custom Quote Today

Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.

Get a Quote
  • High Purity Levels
  • Precision and Reliability
  • Customization Options
Species

Human

Cat.No

ABC-TC3951

Quality Control

All cells test negative for mycoplasma, bacteria, yeast, and fungi.

Product Category Primary Cells
Size/Quantity

1 vial

Cell Type

Mononuclear Cell

Shipping Info

Dry Ice

Growth Conditions

37 ℃, 5% CO2

Source Organ

Peripheral Blood

Disease

Multiple Myeloma

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Diseased Human Peripheral Blood Mononuclear Cells

Description

Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Relapsed/Refractory) are derived from the peripheral blood of patients diagnosed with relapsed or refractory multiple myeloma, a highly aggressive plasma cell malignancy. Round or quasi-round suspended cells with weak adhesion; intracytoplasmic vacuolation and enlarged nucleoli. Cell morphology is characterized by suspended growth of round or quasi-round cells with weak wall adhesion. Typical MM cells show intracytoplasmic vacuolation and enlarged nucleoli. High abnormal monoclonal immunoglobulin expression; Cereblon mutations; overexpression of peptidyl prolyl isomerase A (PPIA) linked to drug resistance.This cell line highly expresses abnormal monoclonal immunoglobulins and has significant drug resistance characteristics, such as resistance to immunomodulators such as lenalidomide and pomalidomide and proteasome inhibitors. The resistance mechanism is related to Cereblon protein mutation and overexpression of peptidyl propionyl isomerase A (PPIA)

View Product Image

Citation

When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Application

  • Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Relapsed/Refractory) are an important model for studying the interaction between tumor resistance mechanisms and the myeloma microenvironment. This cell can be used as an in vitro validation platform for: 1) exploring key targets of resistance (such as Cereblon mutations and PPIA overexpression); 2) evaluating the efficacy of new immunotherapies, including BCMA/CD19 bispecific CAR-T cells and GPRC5D targeting antibodies; 3) developing innovative treatment options such as bispecific antibodies. Its unique resistance characteristics and primary cell characteristics provide an irreplaceable experimental system for precision treatment research of multiple myeloma.

Inquiring Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Relapsed/Refractory)

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

AcceGen Scroll Top Button